Healthcare Review: CLVS, CBAY, PVCT, TNXP, SGEN

Global equity markets fell on Monday as civil unrest in Hong Kong weighed on investor sentiment, while U.S. Treasury debt prices rose over uncertainty sparked by the protests. Stocks on Wall Street opened sharply lower following declines in Europe and Asia as Hong Kong democracy protesters defied volleys of tear gas and police baton charges in one of the biggest political challenges for China since the Tiananmen Square crackdown 25 years ago.

Shares of Clovis Oncology Inc. (NASDAQ: CLVS) jump on a 2x surge in volume in response to its presentation of positive clinical trial results for rucaparib at the ESMO Congress in Madrid, Spain today.In the Phase 2 portion of a Phase 1/2 trial evaluating the overall response rate, safety and tolerability and duration of response in women with platinum-sensitive relapsed germline BRCA-associated ovarian cancer, patients treated with rucaparib showed a disease control rate (a complete response, partial response or stable disease greater than 12 weeks) of 93% (14/15). In addition, 82% (14/17) achieved a RECIST and/or CA-125 response of whom 71% (12/17) achieved a RECIST Partial Response

CymaBay Therapeutics Inc. (NASDAQ: CBAY) completes patient enrollment in its ongoing Phase 2b clinical trial of arhalofenate in patients with gout. The company expects to report top-line results in Q2 2015.The study's primary efficacy endpoint is the prevention of flares.

At the ESMO Congress in Madrid, Spain, Provectus Biopharmaceuticals Inc.(NYSEMKT:PVCT) presented data from an 80-patient single arm Phase 2 trial evaluating the safety and efficacy of PV-10 over 12 months in patients with locally advanced cutaneous melanoma.

Thinly-traded nano cap Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) craters 44% premaket on robust volume after the company reported top-line results from a 205-patient Phase 2b clinical trial of TNX-102 as a chronic bedtime treatment for fibromyalgia.

Seattle Genetics, Inc. (NASDAQ: SGEN) and Takeda Pharmaceutical Co. announce positive results from a 329-patient Phase 3 clinical trial evaluating the safety and efficacy of Adcetris (brentuximab vedotin) as consolidation therapy immediately following an autologous stem cell transplantation (ASCT) in patients with Hodgkin lymphoma HL. The study met its primary endpoint of a statistically significant improvement in progression-free survival PFS compared to placebo. PFS improved 75% as assessed after a minimum of two years post initiation of treatment by an independent central review committee.

Disclosure: This website contains information and opinions based on data obtained from reliable sources, which is current as of the publication date, and does not constitute a recommendation ...

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.